Eva Maria Fenyö
Titel
prof emeritus
Organisation
046-173275
Eva_Maria [dot] Fenyo [at] med [dot] lu [dot] se
Publikationer (hämtat ur Lunds universitets publikationsdatabas)
författare
- 2013
- 2012
- 2011
- Human immunodeficiency virus type 1 biological variation and coreceptor use: from concept to clinical significance.
- Increased Sensitivity to Broadly Neutralizing Antibodies of End-Stage Disease R5 HIV-1 Correlates with Evolution in Env Glycosylation and Charge.
- Inhibition of splicing by serine-arginine rich protein 55 (SRp55) causes the appearance of partially spliced HIV-1 mRNAs in the cytoplasm
- Reply to Redd et al
- Sequence analysis of HIV-1 isolates from Guinea-Bissau: selection of vaccine epitopes relevant in both West African and European countries.
- 2010
- Differences in molecular evolution between switch (R5 to R5X4/X4-tropic) and non-switch (R5-tropic only) HIV-1 populations during infection.
- Enhanced CD4+cellular apoptosis by CCR5-restricted HIV-1 envelope glycoprotein variants from patients with progressive HIV-1 infection
- Flexible use of CCR5 in the absence of CXCR4 use explains the immune deficiency in HIV-1 infected children.
- Frequent CXCR4 tropism of HIV-1 subtype A and CRF02_AG during late-stage disease - indication of an evolving epidemic in West Africa
- Generation of neutralizing antibodies and divergence of SIVmac239 in cynomolgus macaques following short-term early antiretroviral therapy.
- High prevalence of HIV-1, HIV-2 and other sexually transmitted infections among women attending two sexual health clinics in Bissau, Guinea-Bissau, West Africa.
- Increased sensitivity to neutralizing antibodies of end-stage disease R5 HIV-1 is concomitant with reduced gp120 glycosylation and increased plus charge
- Microbial Translocation Correlates with the Severity of Both HIV-1 and HIV-2 Infections
- Serine- and Arginine-rich Proteins 55 and 75 (SRp55 and SRp75) Induce Production of HIV-1 vpr mRNA by Inhibiting the 5 '-Splice Site of Exon 3
- 2009
- Broadly cross-neutralizing activity in plasma of HIV-1 and HIV-2 infected individuals
- Comparison of HIV neutralization assays for use in vaccine research and clinical trials, phase II: results from the NeutNet working group
- Differential Expression of the P-k Histo-Blood Group Antigen in Individuals with the Common P-1 and P-2 Phenotypes Predicts Susceptibility to HIV-1 Infection In Vitro
- International network for comparison of HIV neutralization assays: the NeutNet report.
- Neutralizing activity and cellular immune responses induced in mice after immunization with apoptotic HIV-1/murine leukemia virus infected cells
- Preserved cellular and humoral immune responses in macaques infected with SIVmac239 and subjected to early antiretroviral therapy
- Prevalence and incidence of HIV-1 and HIV-2 before, during and after a civil war in an occupational cohort in Guinea-Bissau, West Africa.
- Studies on toll-like receptor stimuli responsiveness in HIV-1 and HIV-2 infections
- 2008
- Global HIV Vaccine Research Cryorepository - GHRC
- Global HIV Vaccine Research Cryorepository - GHRC
- Identification of a strongly activating human anti-CD40 antibody that suppresses HIV-1 infection
- Primary HIV-1 R5 isolates from end-stage disease display enhanced viral fitness in parallel with increased gp120 net charge.
- Recent advances in the characterization of HIV-1 neutralization assays for standardized evaluation of the antibody response to infection and vaccination
- SIVmac239 is a Potent Immunogen for the Induction of Neutralizing Antibody Response
- SIVmac239 is a potent immunogen for induction of neutralizing antibody response
- Sensitivity of HIV-1 primary isolates to human anti-CD40 antibody-mediated suppression is related to co-receptor use
- Standardization of HIV Neutralization Assays for Use in Vaccine Research and Clinical Trials: Results from the NeutNet Working Group
- Suppression of HIV replication in vitro by CpG and CpG conjugated to the non toxic B subunit of cholera toxin
- 2007
- Asn 362 in gp120 contributes to enhanced fusogenicity by CCR5-restricted HIV-1 envelope glycoprotein variants from patients with AIDS
- Biological and genetic evolution of HIV type 1 in two siblings with different patterns of disease progression
- CD4-independent use of the CCR5 receptor by sequential primary SIVsm isolates
- Frequent intrapatient recombination between HIV-1 R5 and X4 envelopes: Implications for coreceptor switch.
- Introduction: HIV neutralizing antibodies: relevance to pathogenesis and vaccines
- Trends of HIV-1 and HIV-2 prevalence among pregnant women in Guinea-Bissau, West Africa: possible effect of the civil war 1998-1999.
- 2006
- Characterization of the human chemerin receptor - ChemR23/CMKLR1 - as co-receptor for human and simian immunodeficiency virus infection, and identification of virus-binding receptor domains.
- Comparative studies on mucosal and intravenous transmission of simian immunodeficiency virus (SIVsm): evolution of coreceptor use varies with pathogenic outcome.
- Comparative studies on mucosal and intravenous transmission of simian immunodeficiency virus (SIVsm): the kinetics of evolution to neutralization resistance are related to progression rate of disease.
- Isolation of human immunodeficiency virus-type 1 (HIV-1) clones with biological and molecular properties of the primary isolate.
- 2005
- Coreceptor usage of primary HIV type 1 isolates obtained from different lymph node subsets
- Evolution of human immunodeficiency virus type 2 coreceptor usage, autologous neutralization, envelope sequence and glycosylation
- Plaque reduction assays for human and simian immunodeficiency virus neutralisation.
- Plaque-reduction assays for human and simian immunodeficiency virus neutralization.
- Quantitative evaluation of HIV and SIV co-receptor use with GHOST(3) cell assay.
- Quantitative evaluation of HIV and SIV co-receptor use with GHOST(3) cell assay.
- Selection of human immunodeficiency virus type 1 R5 variants with augmented replicative capacity and reduced sensitivity to entry inhibitors during severe immunodeficiency.
- The X4 phenotype of HIV type 1 evolves from R5 in two children of mothers, carrying X4, and is not linked to transmission
- 2004
- 2003
- 2002
- A new cell line-based neutralization assay for primary HIV type 1 isolates
- A new cell line-based neutralization assay for primary HIV type 1 isolates
- Coreceptor change appears after immune deficiency is established in children infected with different HIV-1 subtypes
- Link between the X4 phenotype in human immunodeficiency virus type 1-infected mothers and their children, despite the early presence of R5 in the child
- WHO-UNAIDS Guidelines for Standard HIV Isolation and Characterisation Procedures.
- 2001
- Coreceptor usage of sequential isolates from cynomolgus monkeys experimentally infected with simian immunodeficiency virus (SIVsm)
- Protection of neutralization epitopes in the V3 loop of oligomeric human immunodeficiency virus type I glycoprotein 120 by N-linked oligosaccharides in the V1 region
- Quantitative evaluation of HIV-1 coreceptor use in the GHOST(3) cell assay
